(Total Views: 936)
Posted On: 07/28/2020 7:57:39 PM
Post# of 154141
This is the way I see the CC on Thursday.
They announce that it was " a comprehensive update on the Company’s two trials for COVID-19 patients with mild-to-moderate and severe-to-critical indications", meaning they can release just about any info or data they have available. My theory is that they have some, if not all of the M2M data and I believe they will have some info on S/C,GOOD/BAD/Continue.
Now NP said that they were in talks with both B/P(5 Companies) and big News services, this would be the time that they would be talking to both. Maybe not the news media until Thursday, don't want any accidental releases before then. But if the talks with B/P are fruitful they may PR that at the same time or just after the CC.
Of course all of this is predicated on GOOD M2M data or exceptional S/C readout that stops the trial. I'm actually not sure exactly, the scenario of the S/C readout, if that has to pass thru the FDA first, before any announcement.
They announce that it was " a comprehensive update on the Company’s two trials for COVID-19 patients with mild-to-moderate and severe-to-critical indications", meaning they can release just about any info or data they have available. My theory is that they have some, if not all of the M2M data and I believe they will have some info on S/C,GOOD/BAD/Continue.
Now NP said that they were in talks with both B/P(5 Companies) and big News services, this would be the time that they would be talking to both. Maybe not the news media until Thursday, don't want any accidental releases before then. But if the talks with B/P are fruitful they may PR that at the same time or just after the CC.
Of course all of this is predicated on GOOD M2M data or exceptional S/C readout that stops the trial. I'm actually not sure exactly, the scenario of the S/C readout, if that has to pass thru the FDA first, before any announcement.
(2)
(0)
